MYM V101

Drug Profile

MYM V101

Alternative Names: HIV gp41 vaccine - Mymetics; Mucosal HIV/AIDS vaccine - Mymetics; MYM-V101; MYM-V201; Second generation virosome-based HIV vaccine - Mymetics; Virosome-gp41 mucosal vaccine - Mymetics

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mymetics Corporation
  • Developer Mymetics Corporation; Texas Biomedical Research Institute
  • Class AIDS vaccines; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 11 Apr 2016 Pharmacodynamic results from a preclinical trial in HIV infections released by Mymetics Corporation
  • 06 Apr 2016 Phase-I development is ongoing in Belgium
  • 09 Jul 2014 MYM V101 is available for licensing as of 28 Mar 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top